Inhibition of β-amyloid formation as a therapeutic strategy
- 25 February 1999
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 9 (2) , 135-146
- https://doi.org/10.1517/13543776.9.2.135
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Safety of Tacrine: Clinical Trials, Treatment IND, and Postmarketing ExperienceAlzheimer Disease & Associated Disorders, 1998
- Therapeutic advances: donepezil for the treatment of Alzheimer's diseaseJournal of Clinical Pharmacy & Therapeutics, 1997
- Cell Biology of the Amyloid beta-Protein Precursor and the Mechanism of Alzheimer's DiseaseAnnual Review of Cell Biology, 1994
- beta-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's DiseaseAnnual Review of Pharmacology and Toxicology, 1994
- beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.Proceedings of the National Academy of Sciences, 1993
- Peptide Compositions of the Cerebrovascular and Senile Plaque Core Amyloid Deposits of Alzheimer′s DiseaseArchives of Biochemistry and Biophysics, 1993
- Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.Journal of Biological Chemistry, 1992
- The molecular pathology of Alzheimer's diseaseNeuron, 1991
- The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptorNature, 1987
- Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid proteinBiochemical and Biophysical Research Communications, 1984